Search Within

Myeloma

Formats
  1. Meeting Abstract (556)
  2. Journal Article (360)
  3. Review (36)
  4. Research Letter (21)
  5. Book Section (10)
  6. Guidelines (10)
  7. Correspondence (6)
  8. Editorial (5)
  9. Conference Paper (1)
Groups
  1. Center for Hematologic Malignancies (1005)
  2. Department of Medicine (1005)
  3. Hematologic Malignancies, Division of (1005)
  4. Hematologic Malignancies Research (663)
  5. Survivorship Research (369)
  6. Bone Marrow Transplant (300)

More Groups

People
  1. Alexander Lesokhin (375)
  2. Carl Landgren (336)
  3. Hani Hassoun (335)
  4. Sham Mailankody (293)
  5. Malin Hultcrantz (268)
  6. Heather Landau (246)

More People

Years
  1. 2025 (17)
  2. 2024 (82)
  3. 2023 (115)
  4. 2022 (96)
  5. 2021 (76)
  6. 2020 (95)

More Years

Publications
  1. Blood (316)
  2. Clinical Lymphoma, Myeloma and Leukemia (96)
  3. Journal of Clinical Oncology (85)
  4. Haematologica (41)
  5. Biology of Blood and Marrow Transplantation (29)
  6. Blood Cancer Journal (23)

More Publications

Publishers
  1. American Society of Hematology (338)
  2. Elsevier Inc. (159)
  3. American Society of Clinical Oncology (87)
  4. Nature Publishing Group (84)
  5. Ferrata Storti Foundation (41)
  6. American Association for Cancer Research (34)

More Publishers

Results (1005)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Treatment outcomes and prognostic factors with lenalidomide, bortezomib, and dexamethasone (RVd) alone versus RVd plus autologous stem cell transplantation (ASCT) in African American (AA) patients (pts) with newly diagnosed multiple myeloma (NDMM) in the DETERMINATION phase 3 trial
    Meeting Abstract

    Houde, C. A.; Khan, A.; Jacobus, S. J.; Hassoun, H.; Anderson, L. D. Jr; Merz, L. E.; Zon, R. L.; Efebera, Y.; Buck, T.; Innis-Shelton, R. D.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Dose escalation of ISB 1342, a novel CD38xCD3 bispecific antibody, in patients with relapsed / refractory multiple myeloma (RRMM)
    Meeting Abstract

    Kapoor, P.; Stevens, D. A.; Leleu, X.; Merzoug, K. B.; Karlin, L.; Manier, S.; Chalopin, T.; Hulin, C.; Perrot, A.; Berdeja, J. G.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Updated safety and efficacy results of ABBV-383, a BCMA x CD3 bispecific T-cell redirecting antibody, in a first-in-human phase 1 study in patients with relapsed/refractory multiple myeloma
    Meeting Abstract

    Vij, R.; Kumar, S. K.; D'Souza, A.; McKay, J. T.; Voorhees, P. M.; Chung, A.; Tuchman, S. A.; Korde, N.; Weisel, K.; Teipel, R.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Long-term efficacy and safety of elranatamab monotherapy in the phase 2 magnetismm-3 trial in relapsed or refractory multiple myeloma (RRMM)
    Meeting Abstract

    Tomasson, M.; Iida, S.; Niesvizky, R.; Mohty, M.; Bahlis, N. J.; Martinez-Lopez, J.; Koehne, G.; Otero, P. R.; Prince, H. M.; Viqueira, A.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Selinexor, ixazomib, pomalidomide and dexamethasone in functionally high-risk multiple myeloma: Results from the Myeloma Developing Regimens Using Genomics (MyDRUG) sub-protocol Y3
    Meeting Abstract

    Richter, J.; Zonder, J. A.; Nathwani, N.; Bianchi, G.; Hofmeister, C. C.; Vij, R.; Pianko, M.; Kaur, G.; Hultcrantz, M.; Wozniak, K.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Clinical factors associated with cytokine release syndrome and dosing recommendations for restarting elranatamab following an interruption
    Meeting Abstract

    Niesvizky, R.; Arnulf, B.; Mohty, M.; Nooka, A. K.; Manier, S.; Tomasson, M.; Bahlis, N. J.; Irby, D.; Hibma, J.; Viqueira, A.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Risk factors of smoldering multiple myeloma: Results from the screened iStopMM study
    Meeting Abstract

    Thorsteinsdottir, S.; Sverrisdottir, I.; Rögnvaldsson, S.; Ekberg, S.; Hultcrantz, M.; Vidarsson, B.; Onundarson, P. T.; Agnarsson, B.; Sigurdardottir, M.; Thorsteinsdottir, I.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • SARS-CoV-2 infection does not lead to progression of monoclonal gammopathy of undetermined significance: Results from the population-based iStopMM screening study
    Meeting Abstract

    Palmason, R.; Ekberg, S.; Eythorsson, E.; Rögnvaldsson, S.; Thorsteinsdottir, S.; Crowther, M.; Reed, E. R.; Oskarsson, J.; Sigurdardottir, G. A.; Aspelund, T.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Efficacy and safety of elranatamab in Black patients with relapsed/refractory multiple myeloma (RRMM): A Subgroup analysis of the magnetismm studies
    Meeting Abstract

    Varshavsky-Yanovsky, A.; Jethava, Y.; Stevens, D. A.; Nooka, A. K.; Stiff, P. J.; Perez-Cruz, I.; Leip, E.; Lesokhin, A.
    Blood (2023)

    Fulltext@MSK | Save
  • Whole-genome sequencing reveals distinct mutational signatures in multiple myeloma patients with African ancestry compared with those of non-African ancestry
    Meeting Abstract

    Maclachlan, K. H.; Blaney, P.; Cirrincione, A.; Chu, T. R.; Poos, A. M.; Brown, E. E.; Manasanch, E. E.; Hoering, A.; Hou, L. M.; Gagler, D.; more...
    Blood (2023)

    Fulltext@MSK | Save